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Background: Wnt/β-catenin signaling is a highly conserved pathway in organism evolution and is important in many
biological processes. Overactivation of Wnt/β-catenin signaling is closely related to tumor development and
progression. To identify potent small molecules that can fight aberrant Wnt/β-catenin-mediated cancer, we synthesized
a novel pyrazoline derivative (N-(4-hydroxybenzyl)-1,3,4-triphenyl-4,5-dihydro-1H-pyrazole-5-carboxamide, BHX) to block
Wnt signaling, and determined the absolute configuration of its precursor (ethyl 1,3,4-triphenyl-4,5-dihydro-1H-pyrazole-
5-carboxylate). We then evaluated the inhibitory effect of BHX in vitro and in vivo.
Results: Cell proliferation was assessed in three human cancer cell lines (A549, HT29, and MGC803) in the presence and
absence of BHX using MTS assays. BHX effectively inhibited A549, HT29, and MGC803 cell proliferation with IC50 of
5.43 ± 1.99, 6.95 ± 0.24, and 7.62 ± 1.31 μM, respectively. BHX significantly induced apoptosis and G1 phase arrest in
A549 and MGC803 cells. The β-catenin protein level was markedly reduced in A549 and MGC803 cells under BHX
treatment. The inhibitory effect of BHX in vivo was investigated using a mouse xenograft model. A549 xenograft
growth was suppressed by 50.96% in nude mice treated continuously with 100 mg/kg BHX for 21 d. Weight remained
almost unchanged, which indicates the low toxicity of the compound.
Conclusions: Our data suggest that BHX is a new drug candidate for cancer treatment because of its potent effect on
the Wnt/β-catenin pathway and low toxicity.
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The Wnt signaling pathway is a network of proteins that
are important in embryogenesis and cancer [1-4]. Wnt
ligands trigger at least three different intracellular signaling
cascades: the canonical Wnt pathway, which results in
transcriptional regulation of target genes via β-catenin;
the planar cell polarity pathway, which activates the
small GTPases Rho and Rac; and the Wnt-dependent
calcium/protein kinase C pathway [5]. Among these Wnt
signaling pathways, the canonical Wnt/β-catenin signaling* Correspondence: yanzhaotj@126.com; dyh@mail.cnu.edu.cn
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reproduction in any medium, provided the orβ-catenin is phosphorylated by a destruction complex
formed by proteins that include axin, adenomatous polyp-
osis coli (APC), and glycogen synthase kinase-3 (GSK-3).
The phosphorylated β-catenin becomes ubiquitylated and
is targeted for degradation by proteasome. Following
Wnt binding to transmembrane receptor Frizzled and
low-density lipoprotein receptor-related protein 5/6,
the destruction complex is inhibited, thereby terminating the
phosphorylation of β-catenin by GSK-3. Unphosphorylated
β-catenin accumulates in the cytoplasm and subsequently
translocates to the nucleus where it binds to transcription
factors, such as those belonging to the T cell-specific
transcription factor/lymphoid enhancer-binding factor
(TCF/LEF) family, and activates transcription [7].
Under pathological conditions, β-catenin escapes degrad-
ation and cells retain unregulated activation of canonical. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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β-catenin [8]. Activation of the Wnt/β-catenin signaling
pathway is important in human tumorigenesis, including
colorectal cancer [9], head and neck carcinoma [10],
gastric cancer [11], melanoma [12], leukemia [13], and lung
cancer [14]. The Wnt/β-catenin signaling cascade has
become a major focus in cancer research. Aberrant Wnt
signaling is characterized by the cytoplasmic accumulation
of β-catenin and its subsequent nuclear translocation and
activity [15], which suggests that β-catenin may be a
potential target for drug discovery. Although several
small-molecule modulators of Wnt/β-catenin signaling
have been identified, none of them have been tested
in clinical trials [16].
The pyrazoline family has attracted attention because
of the biological activity, such as anti-inflammatory activ-
ity, of its members. Certain compounds containing the
pyrazoline core also show antidepressant activity [17-19]
and act as multidrug resistance modulators in tumor
cells [20,21]. In this study, we synthesized a novel low
molecular weight pyrazoline derivative, (4S,5R)-N-(4-
hydroxybenzyl)-1,3,4-triphenyl-4,5-dihydro-1H-pyrazole-5-
carboxamid (BHX), which acts as a Wnt/β-catenin signal-
ing inhibitor. The derivative was biologically evaluated
in vitro using TOPflash reporter assay (Additional file 1:
Figure S1). We further evaluated the anticancer activity of
BHX in vitro and in vivo. BHX may be an attractive chemo-
therapeutic agent because of its potent effect on the Wnt/
β-catenin signaling pathway and low toxicity.
Results
Synthesis of BHX
The 1,3-dipolar cycloaddition reaction using nitrili-
mines is a well-known process [22-28]. This synthesis
usually generates the corresponding pyrazolines as a
mixture of regioisomers [29-31], but no direct evidence is
available to reveal which regioisomers are obtained in this
reaction. We prepared nitrilimine 3 by dehydrogenation of
aldehyde hydrazine 1 with chloramine-T [32]. In the pres-
ence of ethyl cinnamate as dipolarophile, in situ-generated
diphenyl nitrilimine 2 yielded the pyrazoline. After hydro-
lysis of compound 4 and subsequent coupling, we
obtained our target compound, BHX (Figure 1). To
confirm the regiochemistry of the cycloaddition for Δ2-
pyrazoline 3, 1H, 13C-HMQC and 1H, 13C-HMBC experi-
ments were performed. We also obtained a single crystal
for compound 3 (Figure 2) to determine the absolute con-
figuration of the cycloadduct by X-ray structural ana-
lysis, which was consistent with the results of spectral
analysis.
BHX inhibits cancer cell proliferation
To characterize the in vitro activity of BHX, we used
three kinds of cell lines with an overactivated Wntsignaling pathway. For each cell line, the IC50 was deter-
mined using MTS assay after 3 d of continuous exposure
to BHX. BHX effectively inhibited human lung cancer cell
line (A549), human colon cancer cell line (HT29), and
human gastric cancer cell line (MGC803) cell proliferation
in a dose-dependent manner, and their IC50 values were
5.43 ± 1.99, 6.95 ± 0.4, and 7.62 ± 1.31 μM, respectively
(Figure 3A). BHX showed lower inhibitory effects on
normal epithelial cells (MCF-10A) (Additional file 2:
Figure S2). Changes in β-catenin protein levels were
determined by western blot analysis. Introduction of
BHX decreased β-catenin protein levels in either A549 or
MGC803 cells in a time-dependent manner.
β-Catenin is also an essential component of the
cell–cell adhesion complex by binding with E-cadherin.
Wnt signaling reportedly regulates E-cadherin expression
[33]. Thus, repression of E-cadherin expression by Slug/
Snail or TCF/β-catenin complex reduces cell–cell adhesion.
To demonstrate the effect of BHX on E-cadherin expres-
sion, E-cadherin levels were determined by western blot
assay. We found that BHX induced the increase in
E-cadherin protein levels (Figure 3B).
BHX causes cell apoptosis and G1 arrest
To study BHX-induced growth inhibition, we evaluated
the ability of BHX to induce A549 and MGC803 cell
death by apoptosis. After treatment with 5 μmol/L BHX
for 3 d, A549 and MGC803 cells displayed a significantly
higher early apoptosis rate than those treated with
the vehicle (P < 0.05). The early apoptosis rate of the
BHX-treated A549 cells (35.5%) was significantly
higher than that of the vehicle-treated cells (1.23%).
Similarly, the early apoptosis rate of the BHX-treated
MGC803 cells (37.2%) was also significantly higher than
that of the vehicle-treated cells (1.61%). However, BHX-
induced late apoptosis was not observed in A549 and
MGC803 cells (Figure 4A). Thus, BHX possibly induced
growth inhibition through an apoptosis-dependent mech-
anism in selected cancer cells. To study the mechan-
ism by which BHX inhibited cancer cell growth, we
also evaluated the changes in cell cycle progression
using flow cytometry. BHX induced G1 arrest in
A549 and MGC803 cell lines. This BHX-associated
G1 arrest was time-dependent (Figure 4B).
BHX inhibits lung cell growth in vivo
We further investigated the inhibitory effect of BHX on
A549 cell tumorigenesis in vivo using a mouse xenograft
model. BALB/c mice were implanted with A549 lung
cells (107 cells/mouse) by subcutaneous injection. When
the tumor volumes were approximately 100 mm3 to
150 mm3, the mice were randomized to receive intraperito-
neal injections of vehicle or BHX at 25, 50, and 100 mg/kg
for 21 consecutive days. Treatment with 100 mg/kg BHX
Figure 1 Scheme for BHX synthesis. 1: (E)-1-Benzylidene-2-phenylhydrazine; 2: diphenyl nitrilimine; 3: ethyl 1,3,4-triphenyl-4,5-dihydro-1H-
pyrazole-5-carboxylate; 4: 1,3,4-triphenyl-4,5-dihydro-1H-pyrazole-5-carboxylic acid; and 5: N-(4-hydroxybenzyl)-1,3,4-triphenyl-4,5-dihydro-1H-
pyrazole-5-carboxamide (BHX).
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(P < 0.05, Figure 5A) and tumor weight (P < 0.05, Figure 5B)
compared with the vehicle group. The inhibition rates in
the 100 and 50 mg/kg groups were 50.96% and 29.44%,
respectively. By contrast, 25 mg/kg BHX had minimal effect
and resulted in an inhibition rate of 10.06%. No significant
weight loss was observed in treatment groups or the vehicleFigure 2 Crystal structure of compound 3. To confirm the regiochemist
compound 3 was obtained. The absolute configuration was determined usgroup (P > 0.05), which indicates that BHX-associated
toxicity was minimal (Figure 5C).
Discussion
Aberrant activation of the Wnt/β-catenin pathway is
reportedly among the most important signal transduction
pathways in the development and progression of manyry of the cycloaddition for Δ2-pyrazoline 3, a single crystal for
ing X-ray structural analysis.
Figure 3 BHX inhibits cancer cell proliferation. (A) A549, MGC803, and HT29 cells were treated with BHX at various concentrations, and the
response was determined using MTS assay. Data are presented as mean ± SD from three independent experiments. (B) A549 and MGC803 cells
were treated with 5 μmol/L BHX for 24 h to 72 h. The β-catenin and E-cadherin levels were measured by western blot assay.
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pathway has drawn significant interest among cancer
researchers. Several molecules have been described to
inhibit Wnt signaling in cells. These molecules may act at
different steps in the Wnt/β-catenin signal transduction
pathway, such as β-catenin/TCF complex, axin2 stability,
CREB-binding protein or porcupine enzyme, and anti-
bodies against Wnt proteins. Other inhibitors have been
suggested to inhibit Wnt/β-catenin signaling indirectly,
such as non-steroid anti-inflammatory drugs and the tyro-
sine kinase inhibitor (Gleevac) [34]. Several compounds
have been tested up to phase I/II clinical trials, but their
clinical efficacy and safety have not been established.
In this study, we synthesized a novel small molecule
BHX. To confirm the regiochemistry of the cycloaddition
for Δ2-pyrazoline 3, a single crystal for compound 3 was
obtained and the absolute configuration was determined
by X-ray structural analysis.
However, the X-ray result differed from that in a previ-
ous report [22], which indicated that the absolute stereo-
chemistry contradicted our findings. We proposed that
cycloaddition could occur from both sides of diphenyl
nitrilimine, and that bond formation was favored by
the π,π-orbital bond overlap. The transition state
showed no stereoselectivity, thus, the Barluenga group,
(4R,5S)-(ethyl 1,3,4-triphenyl-4,5-dihydro-1H-pyrazole-5-
carboxylate, was obtained [35].Then, we determined that BHX downregulated β-catenin
and inhibited cancer cell tumorigenesis in vitro and in vivo.
Our results show that BHX inhibited the growth of cancer
cell lines by inducing G1 arrest. The mechanisms under-
lying the inhibition of Wnt/β-catenin signaling to cause cell
cycle arrest remain unclear, but the involvement of Wnt
target genes c-myc and cyclin D1 in the G1-S transition
may provide an answer [36-38]. Wnt signaling also requires
the regulation of SKP2, which is the F-box subunit of the
ubiquitinligase complex SCFSKP2/p27 degradation pathway,
for Wnt signaling-mediated G1-S transition in human urin-
ary bladder cancer cells [39]. BHX possibly has inhibitory
effects on the transcriptional activities of target genes
c-myc, cyclin D1, and SKP2, which can result in cell
cycle arrest during the G1 phase.
Our results also show that BHX induced the increase
in E-cadherin protein levels in A549 and MGC803
cells. E-cadherin, a prototypic member of the cadherin
single-pass transmembrane glycoprotein family, regulates
cell adhesion in epithelial cells in a Ca2+-dependent manner
[40]. E-cadherin expression level is inversely correlated
with tumorigenesis [41,42]. The loss of E-cadherin
expression at cell–cell contact is consistently observed
at sites of epithelial-mesenchymal transition during
tumor development and progression [43]. The Wnt
target gene Snail has been suggested to function as a
potent repressor of E-cadherin expression [44]. The
Figure 4 BHX causes cell apoptosis and G1 arrest. (A) A549 and MGC803 cells were treated with 5 μmol/L BHX for 72 h. Cell apoptosis was
measured using Annexin V-FITC/PI staining. (B) A549 and MGC803 cells were treated with 5 μmol/L BHX for 24 h to 72 h. The percentage of cells
in each cell cycle phase was determined by quantitation of DNA content by PI staining and flow cytometry. Data are presented as mean ± SD
from three independent experiments.
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possibly related to the inhibition of the transcriptional
activity of Snail.Conclusions
In this study, BHX was synthesized, and the absolute
configuration of its precursor was determined. This
compound showed low nanomolar IC50 values and high
inhibition rate of nude mice xenografts. Thus, BHX rep-
resents a new lead structure for the development of
pharmacotherapies to treat human cancers.Materials and methods
Instrument and reagents
Nuclear magnetic resonance (NMR) spectra were obtained
on a Bruker spectrometer (AV400, 400 MHz). Chemical
shifts (δ) are reported in parts per million relative to
residual undeuterated solvent (internal reference). The
following abbreviations were used to explain the
multiplicities: s = singlet, d = doublet, t = triplet, dd =
doublet of doublets, m = multiplet, and b = broad.
CellTiter 96 cell proliferation assay kit (MTS) was
purchased from Promega (Madison, WI, USA). Rabbit
anti-human β-catenin polyclonal antibody was purchased
Figure 5 BHX inhibits A549 cell tumorigenesis in a xenograft model. Tumor-bearing mice were treated intraperitoneally with vehicle
(DMSO) or BHX (25 and 50 mg/kg) daily for 21 d. Tumor size (A), tumor weight (B), and body weight (C) were measured as described in the
Materials and methods section. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, significant relative to vehicle control.
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Rabbit anti-human E-cadherin polyclonal antibody
was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Annexin V-FITC apoptosis detection
kit (APO-Direct) was purchased from BD Biosciences
(Franklin Lakes, NJ, USA).
Cells and animals
A549, HT29, and MGC803 were obtained from ATCC
(Rockville, MD, USA). A549 and MGC803 cells were
cultured in RPMI 1640 culture medium supplemented
with 10% fetal bovine serum (FBS, HyClone) at 37°Cwith 5% CO2. HT29 cells were cultured in McCoy’s 5A
medium with 10% FBS at 37°C with 5% CO2. MCF-10A
cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM)/F12 culture medium supplemented
with 5% equineserum (HyClone), 20 ng/mL epidermal
growth factor, 0.28 U/mL insulin, 500 ng/mL hydrocorti-
sone, and 100 ng/mL cholera toxin. Female BALB/c mice
(five to six weeks old) were purchased from the Academy
of Military Medical Sciences (Beijing, China). The animals
were maintained under the following standardized, envir-
onmental conditions: 22°C to 28°C, 60% to 70% relative
humidity, 12 h dark/light cycle, and water ad libitum.




Crystal system, Space group Triclinic, P-1
T, K 293 (2)
a (Å) 11.7328 (4)
b (Å) 12.7965 (4)
c (Å) 15.5339 (5)
A (°) 71.355 (2)
β (°) 89.983 (2)
γ (°) 68.099 (2)





θ range, ° 1.89~24.52





Goodness of fit on F2 1.094
(Δ /σ)max 0.004
Δρ, e · Å-3 × 10-3 0.310, -0.338
Ra, wRb 0.0659, 0.0863
a, R = Σ║Fo│-│Fc║/∑│Fo│; b, wR = {[Σw(Fo
2-Fc
2)2]/[Σw(Fo
2)2]}1/2; w = 1/[σ2(Fo
2) +
(0.2000P)2 + 0.0000P], where P = (Fo
2 + 2Fc
2)/3.
Yan et al. Molecular Cancer 2013, 12:116 Page 7 of 10
http://www.molecular-cancer.com/content/12/1/116X-ray crystallography
Single crystals with suitable dimensions of 0.38 mm ×
0.32 mm× 0.15 mm were mounted on glass fibers. Data
collection was performed on Brucker SMART Apex
CCD diffractometer by ω scan technique using graphite-
monochromated Mo-Kαradiation (λ = 0.71073 Å) at 293 K.
Compound 3 was crystallized in the triclinic system,
space group P-1 with a = 11.7328(4) Å, b = 12.7965(4)
Å, c = 15.5339(5) Å, α = 71.355(2)°, β = 89.983(2)°, γ =
68.099(2)°, and V = 2031.50(11) Å3. A total of 31,926
reflections were collected from the θ range of 1.89 to
24.52, and 6750 (Rint = 0.0315 [I > 2(I)])/5079 were unique
and observed. Empirical absorption corrections were per-
formed using SADABS. The structures were solved by
direct methods (SHELXS-97) and refined by full-matrix
least squares on F2 with weight scheme w = 1/[σ2(Fo
2) +
(0.2000P)2 + 0.0000P] (where P = (Fo2 + 2Fc2)/3) using the
SHELXL-97 program suite. All of the non-hydrogen
atoms were refined anisotropically, whereas all of the
hydrogen atoms were added theoretically. Crystallographic
data are summarized in Table 1.
(E)-1-benzylidene-2-phenylhydrazine, 1
Benzaldehyde (306.0 g, 2.9 mol) was slowly added to a
mixture of phenylhydrazine (312.0 g, 2.9 mol) and glacial
acetic acid (3.1 L). The resulting mixture was stirred at
room temperature for 1 h and filtered. The precipitate
was washed with acetic acid and H2O, and then dried
to obtain compound 1 as a white solid (560.0 g,
98.9%). 1H-NMR (400 MHz, CDCl3) δ: 7.65 (m, 4H),
7.36 (m, 2H), 7.27 (m, 3H), 7.11 (m, 2H), and 6.87 (m, 1H).
Ethyl 1,3,4-triphenyl-4,5-dihydro-1H-pyrazole-5-
carboxylate, 3
A mixture of ethyl cinnamate (19.3 g, 109.5 mmol),
chloramine-T trihydrate (48.9 g, 173.6 mmol), and
compound 1 (31.9 g, 162.5 mmol) was dissolved in
methanol (71.8 mL) under dim light. The resulting
solution was stirred under reflux overnight. After
cooling to room temperature, the reaction mixture
was poured into a mixture of ethyl acetate and hexane
(2.0 L, 1:1) and filtered. The filtrate was concentrated to
yield the crude product as a brown oil, which was then puri-
fied by column chromatography (Hex: EtOAc, 100:1) to
produce compound 2 (4.2 g, 10.4%) as a white powder. 1H-
NMR (400 MHz, CDCl3)δ: 7.65 (m, 2H), 7.72 (m, 10H),
7.14 (m, 2H), 6.88 (m, 1H), 4.79 (d, 1H, J = 4.3 Hz), 4.68
(d, 1H, J= 4.3 Hz), 4.22 (m, 2H), and 1.21 (s, 3H, J= 7.1 Hz).
1,3,4-Triphenyl-4,5-dihydro-1H-pyrazole-5-carboxylic acid, 4
LiOH · H2O (0.66 g, 15.9 mmol) was added to a mixture
of compound 2 (3.0 g, 8.1 mmol), tetrahydrofuran
(THF) (18.0 mL), MeOH (6.0 mL), and H2O (6.0 mL).
The resulting solution was stirred for 1 h under roomtemperature. The reaction mixture was concentrated,
dissolved in ethyl acetate (40.0 mL), and then respectively
washed with 5% aqueous HCl (3 × 20 mL) and brine
(3 × 20 mL). The resulting residue was dried over
Na2SO4 and concentrated to produce compound 3
(2.0 g, 72%) as a yellow solid. 1H-NMR (400 MHz,
DMSO-d6)δ: 13.32 (s, 1H), 7.70 (d, 2H, J = 7.1 Hz), 7.28
(m, 10H), 7.11(d, 2H, J = 7.9 Hz), 6.83(t, 1H, J = 7.2 Hz),




chloride (9.0 g, 45.3 mmol), 1-hydroxybenzotriazole (6.1 g,
45.3 mmol), and 4-(aminomethyl)phenol were added to a
mixture of compound 3 (14.1 g, 41.1 mmol) in THF
(140.0 mL). The resulting solution was stirred overnight
under room temperature, and then concentrated to yield
the crude product. The pure product (10.4 g, 56.5%) was
obtained by column chromatography (Hex: EtOAc, 5:1) as
a pale yellow solid. 1H-NMR (400 MHz, DMSO-d6)δ: 9.30
(s, 1H), 8.83 (t, 1H, J = 5.8 Hz), 7.67 (d, 2H, J = 7.1 Hz),
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6.70 (d, 2H, J = 8.8 Hz), 4.93 (d, 1H, J = 4.5 Hz), 4.71
(d, 1H, J = 4.5 Hz), and 4.21 (d, 2H, J = 5.6 Hz).
Cell proliferation assay
For 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) cell pro-
liferation assays, A549, MGC803, and HT29 cells
were seeded in 96-well culture plates at a density of
500 cells to 1,000 cells per well. After 24 h, BHX or
dimethyl sulfoxide (DMSO) was added to the cells at
concentrations between 1.25 and 40 μmol/L. Cell pro-
liferation was determined after 72 husing CellTiter 96
AQueous One Solution (Promega). Absorbance was
recorded at 490 nm using a microplate reader.
Apoptosis assays and cell cycle analysis
Cells were seeded at approximately 50% confluence in
six-well cell culture plates. BHX (5 μmol/L) or DMSO
was added after 24 h, and the cells were collected after
72 h of incubation. Cell apoptosis was measured by
Annexin V-FITC/propidium iodide (PI) staining. Cells
were considered early apoptotic if Annexin V was posi-
tive and PI was negative, and late apoptotic if both
Annexin V and PI were positive. For cell cycle analysis,
cells were rinsed in PBS, fixed in 95% ethanol, pelleted by
centrifugation, and resuspended in RNase A at 50 μg/mL.
After incubation at 37°C for 1 h, 50 g/mL PI was added.
DNA content was determined by flow cytometry, and
the proportion of cells in each cell cycle phase was
determined using ModFit software.
Western blot analysis
Whole cell extracts were lysed in lysis buffer with the
following components: 240 mmol/L Tris (pH 6.8), 2%
sodium dodecyl sulfate (SDS), 0.5% glycerol, 5 mmol/L
EDTA, 1 mg/L aprotinin, 1 mg/L leupeptin, 1 mg/L
peptatin A, 10 mmol/L β-glycerol phosphate, 1 mmol/L
Na3VO4, and 1 mmol/L phenylmethylsulfonyl fluoride.
Lysates were then spun at 12,000 rpm for 10 min to re-
move insoluble materials. The protein concentration was
measured by BCA protein assay (Pierce). Total proteins
were fractionated using SDS–PAGE and transferred to a
polyvinylidenefluoride membrane; blotted with antibodies
against β-catenin, E-cadherin, and β-actin; and detected by
enhanced chemiluminescence (Amersham Biosciences).
Xenograft studies
Female BALB/c mice, weighing 17 g to 23 g, were
implanted subcutaneously with 1 × 107 A549 cells. Tumor
sizes were assessed using the two largest perpendicular
axes. Tumor volume was calculated using the formula
V = (a × b2)/2, where a is length and b is width. When
tumor volumes reached 100 mm3 to 150 mm3, the micewere randomized to drug-treated or vehicle groups
(six mice per group). BHX or vehicle control was
administered by daily intraperitoneal injection at dose
levels of 25, 50, and 100 mg/kg body weight for 21
consecutive days. Tumor growth was monitored every
3 d using a Vernier caliper. Tumor-bearing mice were
assessed for weight loss every 3 d. Tumors were removed
from mice 21 d after vehicle or BHX treatment. Inhibition
rates (antitumor effects) are expressed as T/C% (treatment
groups versus control) by dividing the tumor volumes from
treatment groups with the control group and then multi-
plying the quotient by 100. All animal experiments were
conducted in accordance with the Animal Care Committee
guidelines of Tianjin Medical University Cancer Institute
and Hospital.
Statistical analysis
All values are expressed as mean ± SD. Crude data
were analyzed using SPSS 16.0 statistical software.
The statistical significance of differential findings between
experimental groups and control was determined by
Student’s t-test or Wilcoxon’s test. P values < 0.05 were
considered statistically significant.
Additional files
Additional file 1: Figure S1. BHX dramatically downregulates β-catenin
/TCF-dependent transcriptional activity. To measure Wnt signaling, cells
at a density of 5 × 103 per well were seeded into 24-well plates before
transfection. TOPflash or FOPflash plasmids were co-transfected with
PRL-TK plasmid (internal control). Luciferase activity was measured by
Dual-Glo Luciferase Assay System after cells were cultured for 18 h. The
ratio between firefly luciferase activity (TOPflash/FOPflash) and renilla
activity (internal control) was used for TCF/LEF transcription activity. Data
represent mean ± SD from three independent experiments. Numerous
small molecules were screened for their ability to inhibit Wnt pathway
downstream transcriptional activity using the TOP/FOP reporter assay.
BHX was observed to reduce β-catenin/TCF-dependent transcriptional
activity by 67%. 1: DMSO; 9: BHX.
Additional file 2: Figure S2. Effect of BHX on cell growth of MCF-10A
or A549. MCF-10A and A549 were plated in triplicate. After 24 h, the cells
were treated with DMSO or 3 μmol/L BHX. Viable cell numbers were
counted daily for 4 d by trypan blue exclusion. Results are presented as
percentage of control. Data are presented as mean ± SD from three
independent experiments.
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